Momenta Loses in Appeals Court Over Watson’s Lovenox Copy

Momenta Pharmaceuticals Inc. is unlikely to win its patent-infringement case over copies of the blood-thinner Lovenox, so Watson Pharmaceutics Inc. can sell its version until a trial is held, a U.S. appeals court ruled today.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.